Innate Pharma S.A. (IPH.PA)
EUR 1.98
(-3.37%)
EUR 1.98
(-3.37%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -30.71 Million EUR | 26.83% |
| 2022 | -41.97 Million EUR | 29.46% |
| 2021 | -59.5 Million EUR | 49.45% |
| 2020 | -117.7 Million EUR | 36.09% |
| 2019 | -184.16 Million EUR | -24.61% |
| 2018 | -147.79 Million EUR | -58.06% |
| 2017 | -93.5 Million EUR | 45.18% |
| 2016 | -170.57 Million EUR | -14.39% |
| 2015 | -149.11 Million EUR | -148.2% |
| 2014 | -60.08 Million EUR | -79.12% |
| 2013 | -33.54 Million EUR | -28.61% |
| 2012 | -26.07 Million EUR | 21.88% |
| 2011 | -33.38 Million EUR | -33.37% |
| 2010 | -25.03 Million EUR | 35.64% |
| 2009 | -38.89 Million EUR | -257.32% |
| 2008 | -10.88 Million EUR | -338.56% |
| 2007 | -2.48 Million EUR | 12.94% |
| 2006 | -2.85 Million EUR | -42.12% |
| 2005 | -2 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -35.07 Million EUR | -14.2% |
| 2024 Q2 | -35.07 Million EUR | 1.67% |
| 2023 Q3 | -31.19 Million EUR | -1.43% |
| 2023 Q4 | -30.71 Million EUR | 1.55% |
| 2023 FY | -30.71 Million EUR | 26.83% |
| 2023 Q1 | -31.31 Million EUR | 25.4% |
| 2023 Q2 | -30.75 Million EUR | 1.78% |
| 2022 Q2 | -59.57 Million EUR | 1.38% |
| 2022 Q1 | -60.4 Million EUR | -1.52% |
| 2022 FY | -41.97 Million EUR | 29.46% |
| 2022 Q4 | -41.97 Million EUR | 1.93% |
| 2022 Q3 | -42.79 Million EUR | 28.16% |
| 2021 Q4 | -59.5 Million EUR | 1.33% |
| 2021 Q2 | -87.47 Million EUR | 0.95% |
| 2021 Q1 | -88.31 Million EUR | 24.97% |
| 2021 FY | -59.5 Million EUR | 49.45% |
| 2021 Q3 | -60.3 Million EUR | 31.06% |
| 2020 Q1 | -113.47 Million EUR | 38.39% |
| 2020 FY | -117.7 Million EUR | 36.09% |
| 2020 Q4 | -117.7 Million EUR | 0.66% |
| 2020 Q3 | -118.48 Million EUR | -5.11% |
| 2020 Q2 | -112.72 Million EUR | 0.66% |
| 2019 Q2 | -144.41 Million EUR | 0.83% |
| 2019 Q3 | -184.8 Million EUR | -27.96% |
| 2019 Q4 | -184.16 Million EUR | 0.34% |
| 2019 Q1 | -145.63 Million EUR | 1.46% |
| 2019 FY | -184.16 Million EUR | -24.61% |
| 2018 FY | -147.79 Million EUR | -58.06% |
| 2018 Q4 | -147.79 Million EUR | 0.64% |
| 2018 Q3 | -148.74 Million EUR | -100.28% |
| 2018 Q2 | -74.26 Million EUR | 1.3% |
| 2018 Q1 | -75.24 Million EUR | 19.52% |
| 2017 FY | -93.5 Million EUR | 45.18% |
| 2017 Q1 | -147.24 Million EUR | 13.68% |
| 2017 Q2 | -146.34 Million EUR | 0.61% |
| 2017 Q4 | -93.5 Million EUR | 0.97% |
| 2017 Q3 | -94.41 Million EUR | 35.48% |
| 2016 Q3 | -171.46 Million EUR | -10.08% |
| 2016 FY | -170.57 Million EUR | -14.39% |
| 2016 Q4 | -170.57 Million EUR | 0.52% |
| 2016 Q2 | -155.76 Million EUR | 0.35% |
| 2016 Q1 | -156.32 Million EUR | -4.83% |
| 2015 FY | -149.11 Million EUR | -148.2% |
| 2015 Q2 | -270.78 Million EUR | 0.17% |
| 2015 Q3 | -149.58 Million EUR | 44.76% |
| 2015 Q4 | -149.11 Million EUR | 0.32% |
| 2015 Q1 | -271.24 Million EUR | -351.47% |
| 2014 Q3 | -60.53 Million EUR | 12.96% |
| 2014 FY | -60.08 Million EUR | -79.12% |
| 2014 Q4 | -60.08 Million EUR | 0.75% |
| 2014 Q1 | -69.98 Million EUR | -108.66% |
| 2014 Q2 | -69.54 Million EUR | 0.63% |
| 2013 Q3 | -34.02 Million EUR | -82.3% |
| 2013 FY | -33.54 Million EUR | -28.61% |
| 2013 Q1 | -19.21 Million EUR | 26.33% |
| 2013 Q2 | -18.66 Million EUR | 2.86% |
| 2013 Q4 | -33.54 Million EUR | 1.42% |
| 2012 Q3 | -30.58 Million EUR | 18.96% |
| 2012 FY | -26.07 Million EUR | 21.88% |
| 2012 Q4 | -26.07 Million EUR | 14.73% |
| 2012 Q2 | -37.73 Million EUR | 0.0% |
| 2011 Q4 | -33.38 Million EUR | 0.0% |
| 2011 FY | -33.38 Million EUR | -33.37% |
| 2011 Q2 | -29.65 Million EUR | 0.0% |
| 2010 FY | -25.03 Million EUR | 35.64% |
| 2010 Q2 | -36.39 Million EUR | 0.0% |
| 2010 Q4 | -25.03 Million EUR | 0.0% |
| 2009 Q4 | -38.89 Million EUR | 0.0% |
| 2009 FY | -38.89 Million EUR | -257.32% |
| 2008 FY | -10.88 Million EUR | -338.56% |
| 2007 FY | -2.48 Million EUR | 12.94% |
| 2006 FY | -2.85 Million EUR | -42.12% |
| 2005 FY | -2 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -4201.401% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 84.369% |
| Adocia SA | 127 Thousand EUR | 24282.677% |
| Aelis Farma SA | -16.19 Million EUR | -89.674% |
| Biophytis S.A. | 2.7 Million EUR | 1236.219% |
| Advicenne S.A. | 12.17 Million EUR | 352.255% |
| genOway Société anonyme | 2.97 Million EUR | 1133.041% |
| IntegraGen SA | -709.74 Thousand EUR | -4227.164% |
| Medesis Pharma S.A. | 1.15 Million EUR | 2751.678% |
| Neovacs S.A. | -237.08 Thousand EUR | -12853.895% |
| NFL Biosciences SA | -2.27 Million EUR | -1249.462% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 804.968% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -3597.8% |
| Sensorion SA | 1.37 Million EUR | 2328.378% |
| Theranexus Société Anonyme | 2.44 Million EUR | 1356.549% |
| TME Pharma N.V. | -1.07 Million EUR | -2746.339% |
| Valbiotis SA | -18.13 Million EUR | -69.315% |
| TheraVet SA | 12.78 Thousand EUR | 240319.007% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 1508.807% |
| argenx SE | -1.83 Billion EUR | 98.328% |
| BioSenic S.A. | 28.04 Million EUR | 209.514% |
| Celyad Oncology SA | -6.1 Million EUR | -403.31% |
| DBV Technologies S.A. | -114.95 Million USD | 73.284% |
| Galapagos NV | -157.2 Million EUR | 80.464% |
| Genfit S.A. | -7.61 Million EUR | -303.521% |
| GeNeuro SA | 5.91 Million EUR | 619.626% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | -22.3% |
| Inventiva S.A. | 10.48 Million EUR | 392.802% |
| MaaT Pharma SA | -10.2 Million EUR | -200.951% |
| MedinCell S.A. | 39.5 Million EUR | 177.75% |
| Nanobiotix S.A. | -24.71 Million EUR | -24.25% |
| Onward Medical N.V. | -12.89 Million EUR | -138.188% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 2247.191% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 213.207% |
| Oxurion NV | 10.71 Million EUR | 386.76% |
| Pharming Group N.V. | 99.4 Million EUR | 130.897% |
| Poxel S.A. | 44.55 Million EUR | 168.924% |
| GenSight Biologics S.A. | 16.29 Million EUR | 288.487% |
| Transgene SA | -14.4 Million EUR | -113.145% |
| Financière de Tubize SA | 78.62 Million EUR | 139.061% |
| UCB SA | 2.17 Billion EUR | 101.411% |
| Valneva SE | 82.73 Million EUR | 137.12% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | -65.796% |